THIRTEEN years after its discovery(1), there is still controversy over
the chemical identity of endothelium-derived relaxing factor (EDRF).
Although pharmacological and chemical evidence indicates that EDRF is
nitric oxide(2), other candidates, including S-nitrosocysteine(3,4), c
omplex(5), nitroxyl(6) and hydroxylamine(7), have been proposed to acc
ount for the vasorelaxant properties of EDRF. Such diverse compounds s
hould differ in their stability and in reactivity with oxyhaemoglobin
and with redox-active nucleophiles such as thiols. Here we use a bioas
say to compare the pharmacodynamic profiles of these and other compoun
ds with those of nitric oxide and EDRF. We find that some S-nitrosothi
ols, dinitrosyl-iron-cysteine complex, sodium nitroxyl and hydroxylami
ne can be eliminated as candidates as they are more stable than EDRF a
nd less susceptible to inhibition by oxyhaemoglobin. Co-infusion of cy
steine revealed major differences between the remaining candidates bec
ause it reduced the effect of authentic nitric oxide and EDRF on the b
ioassay tissues but enhanced the survival of S-nitrosocysteine and S-n
itroso-cysteamine. Our results further support the evidence that EDRF,
the pharmacological entity described by Furchgott and Zawadzki(1), is
nitric oxide.